New publication by our researcher Pablo Garcia Valtanen
The recently published work addresses a key need highlighted by the pandemic: the development of thermostable vaccines that do not rely on cold-chain logistics for distribution–especially in resource-limited regions.
This work presents an innovative solid-dose DNA vaccines (SDV) platform, formulated through lyophilization and compaction, allowing needle-free subcutaneous administration and remaining stable even at high temperatures (up to 42ºC).
After demostrating its eficacy and stability using luciferase model, the platform was successfully applied to a DNA vaccine against the Zika virus, inducing robust immune responses and protecting animals from infection.
This technology removes the need for refrigeration, reconstitution, or trained medical personnel–potencially revolutionizing global access to vaccines, particularly in hard-to-reach areas.
Congratulations to Pablo and the team for this major step toward more accesible, effective, and sustainable vaccines!
Full article here: 
https://lnkd.in/dn–HkTV